USD0.000æéå€ååŒÂ  (ET)
15.15MæäŸ¡ç·é¡
æå€±é¡çŽè¿12ã¶æPER
Neurosense Therapeutics Ltd
äž»èŠããŒã¿
0.480å§å€
0.500é«å€
2.78Måºæ¥é«
æå€±é¡çŽè¿12ã¶æPER
æå€±é¡äºæ³PER
--çŽè¿12ã¶æé
åœ
8.53%売買å転ç
0.476忥çµå€
0.432å®å€
760.68K売買代é
æå€±é¡æ ªäŸ¡åçç
-9.71PBRïŒæ ªäŸ¡çŽè³ç£åçïŒ
0.00%çŽè¿12ã¶æé
åœå©åã
-397.11%ç·è³ç£å©çç
2.60052é±é«å€
7.18åºæ¥é«æ¯ç%
-10.21MçŽå©ç
32.56Mæ ªåŒæ°
-0.43661æ ªåœããå©çïŒEPSïŒ
1.57ããŒã¿å€
-2174.98%èªå·±è³æ¬å©çç
0.63052é±å®å€
14.22%æ¯ãå¹
--ç²å©çç
15.15MæäŸ¡ç·é¡
-5.65ãªã¹ã¯ãªã¿ãŒã³
5.80%ãªã¹ã¯ç
Neurosense Therapeutics Ltd ãã¥ãŒã¹
ææ°æ
å ±ããåŸ
ã¡ãã ãã...
åçäºæž¬î
匷åè²·ã
è²·ã
äžç«
売ã
匷å売ã
Neurosense Therapeutics Ltd
NRSN
3
Ionis Pharmaceuticals Inc
IONS
25
ææšî
ææš
売ã(3)
äžç«(0)
è²·ã(0)
ç§»åå¹³å
売ã(6)
äžç«(0)
è²·ã(0)
è²¡åææšî
EPS

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
ç·å£²äžé«

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
Neurosense Therapeutics Ltdã®äŒæ¥æ
å ±î
NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease
äŒæ¥ã³ãŒãNRSN
äŒæ¥åNeurosense Therapeutics Ltd
æé«çµå¶è²¬ä»»è
ãCEOãBen-Noon (Alon)
ãŠã§ããµã€ãhttps://www.neurosense-tx.com/
æ ªäž»çµ±èšî
ãããã質å
Neurosense Therapeutics LtdïŒNRSNïŒã®çŸåšã®æ ªäŸ¡ã¯ãããã§ããïŒ
îNeurosense Therapeutics LtdïŒNRSNïŒã®çŸåšã®æ ªäŸ¡ã¯0.47ã§ãã
Neurosense Therapeutics Ltdã®ãã£ãã«ãŒã·ã³ãã«ã¯äœã§ããïŒ
îNeurosense Therapeutics Ltdã®ãã£ãã«ãŒã·ã³ãã«ã¯NRSNã§ãã
Neurosense Therapeutics Ltdã®52é±é«å€ã¯ãããã§ããïŒ
îNeurosense Therapeutics Ltdã®52é±é«å€ã¯2.60ã§ãã
Neurosense Therapeutics Ltdã®52é±å®å€ã¯ãããã§ããïŒ
îNeurosense Therapeutics Ltdã®52é±å®å€ã¯0.63ã§ãã
Neurosense Therapeutics Ltdã®æäŸ¡ç·é¡ã¯ãããã§ããïŒ
îNeurosense Therapeutics Ltdã®æäŸ¡ç·é¡ã¯15.24Mã§ãã
Neurosense Therapeutics Ltd (NRSN) ã®çŸåšã®è©äŸ¡ã¯ãè²·ããããããŒã«ãããã売ããã®ã©ãã§ããïŒ
îã¢ããªã¹ãã«ãããšãNeurosense Therapeutics LtdïŒNRSNïŒã®ç·åè©äŸ¡ã¯è²·ãã§ãç®æšæ ªäŸ¡ã¯6.50ã§ãã
Neurosense Therapeutics Ltd (NRSN) ã®1æ ªåœããå©çïŒEPS TTMïŒã¯ãããã§ããïŒ
îNeurosense Therapeutics LtdïŒNRSNïŒã®1æ ªåœããå©çïŒEPS TTMïŒã¯-0.44ã§ãã